AUSTRALIA
Australia
Trends and Developments Contributed by: Ben Miller, Alexandra de Zwart, Fiona Deng and Emma Woelke Maddocks Maddocks and its national IP team are recognised for market-leading expertise in strategic IP advice and dis ‑ putes. The firm acts on complex matters for major na ‑ tional and international corporations, particularly in life sciences and pharmaceuticals. The team has a strong track record in high-stakes patent litigation, recently acting in Samsung Bioepis v Janssen (ustekinumab); AUPharma v Mundipharma (controlled release oxyco ‑ done/naloxone); Cipla v BMS (apixaban); AstraZeneca v Pharmacor (ticagrelor); Samsung Bioepis v Formy ‑ con (aflibercept, ranibizumab); Fit-Bioceuticals v Arro ‑
Sydney
Tasmania
tex (colour trade marks); Cipla v Novo Nordisk (liraglu ‑ tide); CSIRO v Urrbrae Foods (high amylose wheat); Orthalign v Navbit (medical devices); and AstraZeneca v Pharmacor (dapagliflozin). With offices in Sydney, Melbourne and Canberra, many of the firm’s lawyers are dual-qualified in scientific and technical disci ‑ plines, and bring exceptional technical insight to solv ‑ ing challenges in the life sciences, pharmaceuticals, biotechnology, medical devices and chemicals indus ‑ tries. The firm combines its IP expertise with leading healthcare, regulatory and technology practices.
Authors
Ben Miller is recognised as one of Australia’s leading IP lawyers, with nearly 30 years of experience in leading IP disputes and transactions. Ben is renowned for his expertise in strategic IP advice, litigation and
Alexandra de Zwart has extensive experience as an IP and life sciences lawyer, and is recognised for her expertise in pharmaceutical patent litigation. As a senior associate in the Maddocks IP team, she delivers
dispute resolution, as well as IP licensing and commercialisation transactions. Ben has worked closely with clients in a wide range of industries, including pharmaceuticals, biopharmaceuticals, biotechnology, animal health, manufacturing and engineering, chemicals, medical devices, consumer goods, food, vitamin supplements and TMT. He has led clients to success in a number of Australia’s leading IP cases.
practical, commercially focused advice and guides clients through complex, multi-jurisdictional patent litigation and other IP disputes. Alexandra has acted in significant IP and life sciences regulatory disputes, including before the Federal Court, the Full Federal Court, the NSW Supreme Court and the Australian Patent Office, combining technical insight with strategic solutions. Her work spans diverse technologies including pharmaceuticals, biotechnology, medical devices, software, hardware, telecommunications, mining and consumer goods.
Fiona Deng is an IP lawyer with broad experience in both contentious and non-contentious matters. She advises clients on protecting, managing and enforcing IP rights across patents, trade marks and copyright, as well as
Emma Woelke is an IP lawyer with dual qualifications in science and law. She advises on both contentious and non-contentious IP matters, including
patents, trade marks, copyright, consumer law and designs. Emma has supported clients across a range of sectors, with particular experience in biotechnology, pharmaceuticals and engineering. Her combined technical and legal expertise enables her to deliver practical, commercially focused solutions for complex IP challenges.
handling disputes involving misleading or deceptive conduct, passing off and breach of contract. Fiona combines technical knowledge with practical, commercially focused strategies to help clients safeguard and maximise the value of their IP.
9 CHAMBERS.COM
Powered by FlippingBook